STAT

DECEMBER 22, 2023

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti.

Labelling 102

Labelling Chemotherapy FDA Patient Care 102

Pharmaceutical Technology

MAY 22, 2023

The US Food and Drug Administration (FDA) has granted approval to AbbVie and Genmab ‘s Epkinly (epcoritamab-bysp) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients. The FDA approval of Epkinly represents a new treatment mechanism of action for third-line DLBCL patients. “As

FDA 52

FDA Adverse Reactions Chemotherapy Patient Care 52

The Checkup by Singlecare

AUGUST 8, 2024

A medication shortage occurs when the demand for a drug is greater than the supply, according to the Food and Drug Administration (FDA). The FDA tracks drug shortages at the national level by obtaining information from drug manufacturers about their ability to produce medications. Many factors cause medication shortages.

Compounding 52

Compounding FDA Compounding Pharmacies Community Pharmacies 52

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Plecanatide is recommended by the ACG for overall symptomatic improvement in IBS-C patients. Lubiprostone : This medication is often recommended for symptomatic improvement in IBS-C patients. 2020;12(1):205. Published 2020 Jan 13.

Health and Personal Care Stores 77

Health and Personal Care Stores Chemotherapy Immunization Compounding 77

The Checkup by Singlecare

MARCH 20, 2025

With a growing demand for GLP-1 agonists, pharmacists may help guide healthcare providers and patients about proper use, potential side effects, and what to expect. Current approved uses of GLP-1 agonists GLP-1 receptor agonists have gained FDA approval for several medical conditions.

FDA 52

FDA Chemotherapy Patient Care 52

pharmaphorum

SEPTEMBER 25, 2020

Furthermore, the duration of response with the PD-1 checkpoint inhibitor was nearly five times longer at 29 months versus just over six months with frontline chemotherapy. Another contender meanwhile also reported new data at ESMO.

Chemotherapy 75

Chemotherapy Labelling Patient Care FDA 75

pharmaphorum

SEPTEMBER 8, 2020

Beyond significant cost savings, biosimilar uptake has been shown to simultaneously improve patient access, varying by country. A subsequent change in guidance moved this biologic to a first-line treatment, resulting in an increase in the number of patients who could receive this much-needed treatment by 104%.

Chemotherapy 99

Chemotherapy Patient Care Vaccines FDA 99